Skip to Main Content
DownloadHi-Res Photo

Shari Damast, MD

Associate Professor of Therapeutic Radiology; Chief, Gynecologic Radiotherapy Program, Therapeutic Radiology

Contact Information

Shari Damast, MD

Office Location

Mailing Address

  • Therapeutic Radiology

    PO Box 208040

    New Haven, CT 06520-8040

    United States

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Damast’s research is focused on the use of modern radiotherapeutic modalities including image-guided intensity-modulated radiation therapy and image-guided high-dose-rate brachytherapy for women with gynecologic malignancies. She studies how these therapies are integrated into management and how they impact outcomes of women. She has a particular interest in patient-centered outcomes, quality of life, vaginal health and sexual functioning.

Coauthors

Research Interests

Brachytherapy; Radiotherapy

Selected Publications

  • Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma?Yoon J, Fitzgerald H, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ, Hathout L. Does Prophylactic Paraortic Lymph Node Irradiation Improve Outcomes in Women With Stage IIIC1 Endometrial Carcinoma? Practical Radiation Oncology 2022, 12: e123-e134. PMID: 34822999, DOI: 10.1016/j.prro.2021.10.002.
  • An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva.Li JY, Arkfeld CK, Tymon-Rosario J, Webster E, Schwartz P, Damast S, Menderes G. An evaluation of prognostic factors, oncologic outcomes, and management for primary and recurrent squamous cell carcinoma of the vulva. Journal Of Gynecologic Oncology 2022, 33: e13. PMID: 34910394, PMCID: PMC8899873, DOI: 10.3802/jgo.2022.33.e13.
  • Dosimetric study of Varian Universal Multi-Channel Cylinder System for High-Dose-Rate 192Ir Brachytherapy.Tien CJ, Damast S, Chen ZJ. Dosimetric study of Varian Universal Multi-Channel Cylinder System for High-Dose-Rate 192Ir Brachytherapy. Brachytherapy 2022, 21: 244-254. PMID: 34996715, DOI: 10.1016/j.brachy.2021.11.001.
  • A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi DA, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario JR, Harold JA, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin JA, Choi J, Santin AD. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. Cancer 2022, 128: 1206-1218. PMID: 34875107, DOI: 10.1002/cncr.34025.
  • Secondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation Therapy.Damast S, Chino J. Secondary Prevention, Not Secondary Importance: Embracing Survivorship Concerns and HRT After Cervical Cancer Radiation Therapy. International Journal Of Radiation Oncology, Biology, Physics 2022, 112: 414-416. PMID: 34998535, DOI: 10.1016/j.ijrobp.2021.09.028.
  • Improving Radiation Therapy for Cervical Cancer.Kidd E, Harkenrider M, Damast S, Fields E, Chopra S, Chino J. Improving Radiation Therapy for Cervical Cancer. International Journal Of Radiation Oncology, Biology, Physics 2022, 112: 841-848. PMID: 35190051, DOI: 10.1016/j.ijrobp.2021.12.006.
  • Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic.Damast S, Tien CJ, Young M, Altwerger G, Ratner E. Single application hybrid interstitial brachytherapy for cervical cancer: an institutional approach during the COVID-19 pandemic. Journal Of Contemporary Brachytherapy 2022, 14: 66-71. PMID: 35233237, PMCID: PMC8867238, DOI: 10.5114/jcb.2022.113058.
  • Radiation therapy in the definitive management of medically inoperable endometrial cancer.Chin C, Damast S. Radiation therapy in the definitive management of medically inoperable endometrial cancer. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2022, 32: 323-331. PMID: 35256419, DOI: 10.1136/ijgc-2021-002532.
  • A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer.Hathout L, Wang Y, Wang Q, Vergalasova I, Elshaikh MA, Dimitrova I, Damast S, Li JY, Fields EC, Beriwal S, Keller A, Kidd EA, Usoz M, Jolly S, Jaworski E, Leung EW, Donovan E, Taunk NK, Chino J, Natesan D, Russo AL, Lea JS, Albuquerque KV, Lee LJ. A Multi-Institutional Analysis of Adjuvant Chemotherapy and Radiation Sequence in Women With Stage IIIC Endometrial Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 110: 1423-1431. PMID: 33677053, DOI: 10.1016/j.ijrobp.2021.02.055.
  • Benefits of a Multidisciplinary Women's Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy.Li JY, D'Addario J, Tymon-Rosario J, Menderes G, Young MR, Johung K, Ratner E, Minkin MJ, Damast S. Benefits of a Multidisciplinary Women's Sexual Health Clinic in the Management of Sexual and Menopausal Symptoms After Pelvic Radiotherapy. American Journal Of Clinical Oncology 2021, 44: 143-149. PMID: 33755031, DOI: 10.1097/COC.0000000000000800.
  • A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi DA, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793). Annals Of Oncology : Official Journal Of The European Society For Medical Oncology / ESMO 2021, 32: 1045-1046. PMID: 33932502, DOI: 10.1016/j.annonc.2021.04.013.
  • Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer.Laird J, Leventhal J, Kanowitz J, Damast S. Radiation Recall Dermatitis After Capecitabine in a Patient With Triple Negative Breast Cancer. Practical Radiation Oncology 2021, 11: 448-452. PMID: 34157449, DOI: 10.1016/j.prro.2021.06.001.
  • NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal Of The National Comprehensive Cancer Network : JNCCN 2021, 19: 888-895. PMID: 34416706, DOI: 10.6004/jnccn.2021.0038.
  • Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer.Damast S, Fields E, Kidd E, Harkenrider M, Chopra S, Chino J. Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer. International Journal Of Radiation Oncology, Biology, Physics 2021, 111: 299-306. PMID: 34473967, DOI: 10.1016/j.ijrobp.2021.05.002.
  • Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy.Li JY, Park HS, Huang GS, Young MR, Ratner E, Santin A, Damast S. Prognostic impact of mismatch repair deficiency in high- and low-intermediate-risk, early-stage endometrial cancer following vaginal brachytherapy. Gynecologic Oncology 2021, 163: 557-562. PMID: 34602287, DOI: 10.1016/j.ygyno.2021.09.018.
  • Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy.Hochreiter A, Kelly JR, Young MR, Litkouhi B, Black JD, Stromberger C, Higgins S, Schwartz PE, Damast S. Outcomes and relapse patterns of stage IB grade 2 or 3 endometrial cancer treated with adjuvant vaginal brachytherapy. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2020, 30: 48-55. PMID: 31722964, DOI: 10.1136/ijgc-2019-000675.
  • Stage III uterine serous carcinoma: modern trends in multimodality treatment.Li JY, Young MR, Huang G, Litkouhi B, Santin A, Schwartz PE, Damast S. Stage III uterine serous carcinoma: modern trends in multimodality treatment. Journal Of Gynecologic Oncology 2020, 31: e53. PMID: 32266802, PMCID: PMC7286763, DOI: 10.3802/jgo.2020.31.e53.
  • NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal Of The National Comprehensive Cancer Network : JNCCN 2020, 18: 660-666. PMID: 32502976, DOI: 10.6004/jnccn.2020.0027.
  • Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study.Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN. Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: A multi-institutional cohort study. Gynecologic Oncology 2020, 159: 17-22. PMID: 32709539, PMCID: PMC7541557, DOI: 10.1016/j.ygyno.2020.07.016.
  • Radiation for Cancers of the Uterine Corpus and Cervix: Incremental Steps, and Glimmers of the Future.Chino J, Damast S, Kidd E, Harkenrider M, Albuquerque K, Kamrava M. Radiation for Cancers of the Uterine Corpus and Cervix: Incremental Steps, and Glimmers of the Future. International Journal Of Radiation Oncology, Biology, Physics 2020, 108: 839-845. PMID: 33069345, DOI: 10.1016/j.ijrobp.2020.06.012.
  • Feasibility of deploying a U.S. simulation-based gynecological brachytherapy educational workshop to an international setting.Damast S, Felder S, Fields E, Singer L. Feasibility of deploying a U.S. simulation-based gynecological brachytherapy educational workshop to an international setting. Brachytherapy 2020, 19: 777-782. PMID: 33221261, DOI: 10.1016/j.brachy.2020.09.015.
  • Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy.Stahl JM, Qian JM, Tien CJ, Carlson DJ, Chen Z, Ratner ES, Park HS, Damast S. Extended duration of dilator use beyond 1 year may reduce vaginal stenosis after intravaginal high-dose-rate brachytherapy. Supportive Care In Cancer : Official Journal Of The Multinational Association Of Supportive Care In Cancer 2019, 27: 1425-1433. PMID: 30187220, DOI: 10.1007/s00520-018-4441-5.
  • Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2019, 17: 64-84. PMID: 30659131, DOI: 10.6004/jnccn.2019.0001.
  • Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology.Damast S, Jeffery DD, Son CH, Hasan Y, Carter J, Lindau ST, Jhingran A. Literature Review of Vaginal Stenosis and Dilator Use in Radiation Oncology. Practical Radiation Oncology 2019, 9: 479-491. PMID: 31302301, PMCID: PMC7944435, DOI: 10.1016/j.prro.2019.07.001.
  • Development of a Multi-Institutional Simulation-Based Gynecologic Brachytherapy Curriculum.Singer L, Damast S, Lin L, Taunk N, Lee LJ, Albuquerque K, Chino J, Petereit D, Joyner M, Fields E. Development of a Multi-Institutional Simulation-Based Gynecologic Brachytherapy Curriculum. International Journal Of Radiation Oncology, Biology, Physics 2019, 104: 1175-1176. PMID: 31327414, DOI: 10.1016/j.ijrobp.2019.05.023.
  • Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Wyse E, McMillian NR, Scavone J. Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2019, 17: 1374-1391. PMID: 31693991, DOI: 10.6004/jnccn.2019.0053.
  • Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma.Stahl JM, Damast S, Bledsoe TJ, An Y, Verma V, Yu JB, Young MR, Lester-Coll NH. Cost-effectiveness of adjuvant intravaginal brachytherapy in high-intermediate risk endometrial carcinoma. Brachytherapy 2018, 17: 399-406. PMID: 29275078, DOI: 10.1016/j.brachy.2017.11.012.
  • Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline.Carter J, Lacchetti C, Andersen BL, Barton DL, Bolte S, Damast S, Diefenbach MA, DuHamel K, Florendo J, Ganz PA, Goldfarb S, Hallmeyer S, Kushner DM, Rowland JH. Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology 2018, 36: 492-511. PMID: 29227723, DOI: 10.1200/JCO.2017.75.8995.
  • Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology.Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, George S, Han E, Higgins S, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network : JNCCN 2018, 16: 170-199. PMID: 29439178, DOI: 10.6004/jnccn.2018.0006.
  • Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer.Lester-Coll NH, Young MR, Park HS, Ratner ES, Litkouhi B, Damast S. Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2017, 27: 1904-1911. PMID: 28763364, DOI: 10.1097/IGC.0000000000001095.
  • Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer.Qian JM, Stahl JM, Young MR, Ratner E, Damast S. Impact of vaginal cylinder diameter on outcomes following brachytherapy for early stage endometrial cancer. Journal Of Gynecologic Oncology 2017, 28: e84. PMID: 29027402, PMCID: PMC5641534, DOI: 10.3802/jgo.2017.28.e84.
  • Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients.Stahl JM, Park HS, Silasi DA, Azodi M, Damast S. Influence of robotic-assisted laparoscopic hysterectomy on vaginal cuff healing and brachytherapy initiation in endometrial carcinoma patients. Practical Radiation Oncology 2016, 6: 226-232. PMID: 27364883, DOI: 10.1016/j.prro.2015.09.015.
  • Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review.Damast S, Takiar V, McCarthy S, Higgins SA. Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. Gynecologic Oncology Reports 2016, 17: 89-92. PMID: 27536721, PMCID: PMC4975702, DOI: 10.1016/j.gore.2016.08.002.
  • Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base.Lester-Coll NH, Park HS, Rutter CE, Corso CD, Young MR, Ratner ES, Litkouhi B, Decker RH, Yu JB, Damast S. Who benefits from chemoradiation in stage III-IVA endometrial cancer? An analysis of the National Cancer Data Base. Gynecologic Oncology 2016, 142: 54-61. PMID: 27151429, DOI: 10.1016/j.ygyno.2016.04.544.
  • Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.Young MR, Higgins SA, Ratner E, Yu JB, Mani S, Silasi DA, Azodi M, Rutherford T, Schwartz PE, Damast S. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2015, 25: 431-9. PMID: 25621409, PMCID: PMC5603450, DOI: 10.1097/IGC.0000000000000376.
  • Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma.Park HS, Ratner ES, Lucarelli L, Polizzi S, Higgins SA, Damast S. Predictors of vaginal stenosis after intravaginal high-dose-rate brachytherapy for endometrial carcinoma. Brachytherapy 2015, 14: 464-70. PMID: 25887343, DOI: 10.1016/j.brachy.2015.03.001.
  • Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer: A Single Institution Retrospective Study of 47 Cases and Review of the Literature.Gressel GM, Lundsberg LS, Altwerger G, Katchi T, Azodi M, Schwartz PE, Ratner ES, Damast S. Factors Predictive of Improved Survival in Patients With Brain Metastases From Gynecologic Cancer: A Single Institution Retrospective Study of 47 Cases and Review of the Literature. International Journal Of Gynecological Cancer : Official Journal Of The International Gynecological Cancer Society 2015, 25: 1711-6. PMID: 26332394, PMCID: PMC4623851, DOI: 10.1097/IGC.0000000000000554.
  • High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma.Damast S, Higgins SA, Ratner E, De Leon MC, Mani S, Silasi DA, Azodi M, Santin A, Rutherford T, Schwartz PE. High-dose-rate vaginal brachytherapy with chemotherapy for surgically staged localized uterine serous carcinoma. Journal Of Contemporary Brachytherapy 2015, 7: 35-40. PMID: 25829935, PMCID: PMC4371058, DOI: 10.5114/jcb.2015.48539.
  • Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer.Damast S, Alektiar K, Eaton A, Gerber NK, Goldfarb S, Patil S, Jia R, Leitao M, Carter J, Basch E. Comparative patient-centered outcomes (health state and adverse sexual symptoms) between adjuvant brachytherapy versus no adjuvant brachytherapy in early stage endometrial cancer. Annals Of Surgical Oncology 2014, 21: 2740-54. PMID: 24619493, DOI: 10.1245/s10434-014-3562-4.
  • Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.Kiess AP, Damast S, Makker V, Kollmeier MA, Gardner GJ, Aghajanian C, Abu-Rustum NR, Barakat RR, Alektiar KM. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer. Gynecologic Oncology 2012, 127: 321-5. PMID: 22850412, DOI: 10.1016/j.ygyno.2012.07.112.
  • Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy.Damast S, Alektiar KM, Goldfarb S, Eaton A, Patil S, Mosenkis J, Bennett A, Atkinson T, Jewell E, Leitao M, Barakat R, Carter J, Basch E. Sexual functioning among endometrial cancer patients treated with adjuvant high-dose-rate intra-vaginal radiation therapy. International Journal Of Radiation Oncology, Biology, Physics 2012, 84: e187-93. PMID: 22572074, PMCID: PMC5538259, DOI: 10.1016/j.ijrobp.2012.03.030.
  • Impact of dose on local failure rates after image-guided reirradiation of recurrent paraspinal metastases.Damast S, Wright J, Bilsky M, Hsu M, Zhang Z, Lovelock M, Cox B, Zatcky J, Yamada Y. Impact of dose on local failure rates after image-guided reirradiation of recurrent paraspinal metastases. International Journal Of Radiation Oncology, Biology, Physics 2011, 81: 819-26. PMID: 20888133, DOI: 10.1016/j.ijrobp.2010.06.013.
  • Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.Damast S, Ho AY, Montgomery L, Fornier MN, Ishill N, Elkin E, Beal K, McCormick B. Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era. International Journal Of Radiation Oncology, Biology, Physics 2010, 77: 1105-12. PMID: 19879068, DOI: 10.1016/j.ijrobp.2009.06.042.
  • Do metallic ports in tissue expanders affect postmastectomy radiation delivery?Damast S, Beal K, Ballangrud A, Losasso TJ, Cordeiro PG, Disa JJ, Hong L, McCormick BL. Do metallic ports in tissue expanders affect postmastectomy radiation delivery? International Journal Of Radiation Oncology, Biology, Physics 2006, 66: 305-10. PMID: 16904530, DOI: 10.1016/j.ijrobp.2006.05.017.
  • Changes in cerebrospinal fluid neurochemistry during pregnancy.Altemus M, Fong J, Yang R, Damast S, Luine V, Ferguson D. Changes in cerebrospinal fluid neurochemistry during pregnancy. Biological Psychiatry 2004, 56: 386-92. PMID: 15364035, DOI: 10.1016/j.biopsych.2004.06.002.

Clinical Trials

ConditionsStudy Title
CervixA Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)
Other Female GenitalA Phase III Randomized Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Edit Profile